A model of the ocular pharmacokinetics involved in the therapy of neovascular age-related macular degeneration with ranibizumab.
about
ARMS2 A69S polymorphism is associated with the number of ranibizumab injections needed for exudative age-related macular degeneration in a pro re nata regimen during 4 years of follow-up.Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times.
P2860
A model of the ocular pharmacokinetics involved in the therapy of neovascular age-related macular degeneration with ranibizumab.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
A model of the ocular pharmaco ...... degeneration with ranibizumab.
@en
type
label
A model of the ocular pharmaco ...... degeneration with ranibizumab.
@en
prefLabel
A model of the ocular pharmaco ...... degeneration with ranibizumab.
@en
P2093
P2860
P1476
A model of the ocular pharmaco ...... degeneration with ranibizumab.
@en
P2093
Derek J Saunders
Philipp S Muether
Sascha Fauser
P2860
P304
P356
10.1136/BJOPHTHALMOL-2015-306771
P407
P577
2015-05-08T00:00:00Z